Dr. Mathieu Simon to Retire as Cellectis´ Chief Operating Officer; Elsy Boglioli Named as Successor
(WorldNews France)

March 13, 2018 - New York (N.Y.) -Cellectis(Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that Dr. Mathieu Simon is retiring as Executive Vice President and Chief Operating Officer, effective immediately. Following a smooth...